Prevention and Prophylaxis of Malaria in Older Travelers

Wed, 2/4/09 - 4:04pm
0 Comments
2719 reads

Citation:

Pages 36 - 45

Authors:

Justin A. Yax, DO, Curtis D. Collins, PharmD, MS,
and Preeti N. Malani, MD

Author Affiliations:

Dr. Yax is from the Division of Infectious Diseases, Department of Medicine, University of Michigan Health System; Dr. Collins is from the Department of Pharmacy Services, University of Michigan Health System; and Dr. Malani is from the Division of Infectious Diseases and the Division of Geriatric Medicine, Department of Internal Medicine, University of Michigan Health System, Veterans Affairs Ann Arbor Healthcare System Geriatric Research, Education, and Clinical Center (GRECC), Ann Arbor, MI.

References:

1. Schwartz E, Sadetzki S, Murad H, Raveh D. Age as a risk factor for severe Plasmodium falciparum malaria in nonimmune patients. Clin Infect Dis 2001;33:1774-1777. Epub 2001 Oct 12.
2. Gjørup IE, Rønn A. Malaria in elderly nonimmune travelers. J Travel Med 2002;9:91-93.
3. Jensenius M, Rønning EJ, Blystad M, et al. Low frequency of complications in imported falciparum malaria: A review of 222 cases in south-eastern Norway. Scand J Infect Dis 1999;31:73-78.
4. World Health Organization. Environmental health risks. International Travel and Health 2007; World Health Organization; 2007:30-48. Available at: www.who.int/ith/en/. Accessed June 14, 2007.
5. Insect repellents. The Medical Letter on Drugs and Therapeutics 2003;45(1157):41-44.
6. Gupta RK, Rutledge LC. Laboratory evaluation of controlled-release repellent formulations on human volunteers under three climatic regimens. J Am Mosq Control Assoc 1989;5:52-55.
7. Picaridin—A new insect repellent. The Medical Letter on Drugs and Therapeutics 2005;47(1210):45-48.
8. Fradin MS, Day JF. Comparative efficacy of insect repellents against mosquito bites. N Engl J Med 2002;347:13-18.
9. Salako LA. Toxicity and side-effects of antimalarials in Africa: A critical review. Bull World Health Organ 1984;(62 suppl):63-68.
10. Eliades JM, Shah S, Nguyen-Dinh P, et al. Malaria surveillance—United States, 2003. MMWR Surveill Summ 2005;54(2):25-40.
11. Steffen R, Fuchs E, Schildknecht J, et al. Mefloquine compared with other malaria chemoprophylactic regimens in tourists visiting east Africa. Lancet 1993;341:1299-1303.
12. Stürchler D, Handschin J, Kaiser D, et al. Neuropsychiatric side effects of mefloquine. New Engl J Med 1990;322:1752-1753.
13. World Health Organization: Mefloquine: Update on safety issues. WHO Drug Info 1996;10:58-61.
14. Happi CT, Gbotosho GO, Folarin OA, et al. Confirmation of emergence of mutations associated with atovaquone/proguanil resistance in unexposed Plasmodium falciparum isolates from Africa. Malar J 2006;5:82.
15. Camus D, Djossou F, Schilthuis HJ, et al. Atovaquone-proguanil versus chloroquine-proguanil for malaria prophylaxis in nonimmune pediatric travelers: Results of an international, randomized, open-label study. Clin Infect Dis 2004;38:1716-1723. Epub 2004 May 27.
16. Centers for Disease Control and Prevention. Travelers’ Health: Yello Book. Health Information for International Travel, 2005-2006. DHHS, Atlanta, GA, 2001. Available at: www.cdc.gov/travel/yb/. Accessed June 15, 2007.
17. Magill AJ. The prevention of malaria. Prim Care 2002;29:815-842.
18. Centers for Disease Control (CDC). Adverse reactions to Fansidar and updated recommendations for its use in the prevention of malaria. MMWR Morb Mortal Wkly Rep 1985;33(51-52):713-714.
19. Weiss WR, Oloo AJ, Johnson A, et al. Daily primaquine is effective for prophylaxis against falciparum malaria in Kenya: Comparison with mefloquine, doxycycline, and chloroquine plus proguanil. J Infect Dis 1995;171:1569-1575.
20. Barnes AJ, Ong EL, Dunbar EM, et al. Failure of chloroquine and proguanil prophylaxis in travellers to Kenya. Lancet 1991;338:1338-1339.